Carcinoma, Transitional CellPhase 3FORAGER-2NCT07218380
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
A Phase 3 study testing Vepugratinib, EV and Pembrolizumab in people with Carcinoma, Transitional Cell and Urinary Bladder Neoplasms, run by Eli Lilly and Company at 276 sites in 19 countries.
Trial summary
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
- What is being tested?
- Vepugratinib, EV and Pembrolizumab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 450 participants
- Where
- 276 sitesin 19 countries
- Study dates
- 12 Dec 2025to May 2033
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present.
- Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer.
- Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Have adequate laboratory parameters
Who cannot join
- Have received prior systemic therapy for locally advanced or metastatic urothelial cancer (mUC).
- Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria for Adverse Events ([CTCAE] version 5.0) from prior neoadjuvant or adjuvant systemic therapy.
- Have ongoing sensory or motor neuropathy of Grade 2 or higher
- Have untreated or uncontrolled central nervous system (CNS) involvement or any history of leptomeningeal disease.
- Current evidence corneal keratopathy or retinal disorder confirmed by ocular examination at screening.
Trial locations and contacts
276 sites in 19 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
276 sites in 19 countries
United States64 sites, 63 recruiting
- Recruiting
USO-Texas Oncology-Central/South Texas
Austin, Texas, 78731
Michael Lattanzi
- Recruiting
Johns Hopkins Hospital
Baltimore, Maryland, 21287
Jean Hoffman-Censits
- Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
225-215-1185
Victor Lin
- Recruiting
World Research Link
Baytown, Texas, 77521
833-832-8328
Amir Rasheed
- Not yet recruiting
St. Luke's Cancer Institute: Boise
Boise, Idaho, 83712
Peyman Haghighat
- Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts, 02114
617-724-4000
Xin Gao
- Not yet recruiting
Levine Cancer Institute
Charlotte, North Carolina, 28204
980-442-6410
Earle Burgess
- Recruiting
Oncology Specialists of Charlotte
Charlotte, North Carolina, 28207
Nasfat Shehadeh
- Recruiting
University of Illinois at Chicago
Chicago, Illinois, 60612
Karine Tawagi
- Not yet recruiting
University of Chicago Medical Center
Chicago, Illinois, 60637
773-702-1152
Randy Sweis
- Not yet recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219
Robert Franklin
- Not yet recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T
Columbus, Ohio, 43210
Peng Wang
- Not yet recruiting
Parkland Health and Hospital System
Dallas, Texas, 75235
214-648-4180
Tian Zhang
- Recruiting
UT Southwestern Medical Center
Dallas, Texas, 75390
214-648-4180
Tian Zhang
- Not yet recruiting
AdventHealth Medical Group - Porter
Denver, Colorado, 80210
303-715-7030
Yousuf Gaffar
- Recruiting
Karmanos Cancer Institute
Detroit, Michigan, 48201
Yusra Shao
- Not yet recruiting
Brigitte Harris Cancer Pavilion
Detroit, Michigan, 48202
Muhammad Shahid
- Recruiting
Astera Cancer Care
East Brunswick, New Jersey, 08816
732-390-7750
Phillip Reid
- Not yet recruiting
Endeavor Health
Evanston, Illinois, 60201
847-570-2112
Ami Badami
- Recruiting
Parkview Research Center at Parkview Regional Medical Center
Fort Wayne, Indiana, 46845
Kushal Naha
- Not yet recruiting
James M Stockman Cancer Institute
Frederick, Maryland, 21702
Saro Sarkisian
- Recruiting
Colorado West Healthcare System - Grand Valley Oncology
Grand Junction, Colorado, 81505
970-644-4460
Jonathan King
- Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4009
Michael Glover
- Recruiting
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Tareq Salous
- Recruiting
Franciscan Health
Indianapolis, Indiana, 46237
Patrick Heckman
- Recruiting
Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine
Irvine, California, 92612
Nataliya Mar
- Not yet recruiting
Lancaster General Hospital - Ann B Barshinger Cancer Institute
Lancaster, Pennsylvania, 17601
Matthew Brennan
- Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
Ammar Yousif
- Suspended
University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536
- Not yet recruiting
Accellacare of Duly
Lisle, Illinois, 60532
Brian Myre
- Not yet recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Anuradha kunthur
- Recruiting
TRIO-US (Translational Research in Oncology-US)
Los Angeles, California, 90024
Brenda Williams
- Recruiting
UCLA Hematology/Oncology - Santa Monica
Los Angeles, California, 90404
Alexandra Drakaki
- Recruiting
Nova Oncology
McAllen, Texas, 78504
956-234-4400
Raghad Muhsin Abdul Karim, MD
- Recruiting
Mary Bird Perkins Cancer Center - Metairie
Metairie, Louisiana, 70002
225-215-1185
Victor Lin
- Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, 37203
SMO Sarah Cannon Research Inst.
- Recruiting
SCRI Oncology Partners
Nashville, Tennessee, 37203
Benjamin Garmezy
- Recruiting
Tennessee Oncology
Nashville, Tennessee, 37203
Kathryn Beckermann
- Not yet recruiting
Yale-New Haven Hospital
New Haven, Connecticut, 06510
203-200-4822
Joseph Kim
- Not yet recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
504-842-3910
Brian Halbert
- Recruiting
Columbia University Irving Medical Center
New York, New York, 10032
Alexander Wei
- Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
646-888-4737
Gopakumar Iyer
- Not yet recruiting
Weill Cornell Medical College
New York, New York, 10065
317-217-9178
Rohit Jain
- Recruiting
USO - Virginia Oncology Associates
Norfolk, Virginia, 23502
Mark Fleming
- Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center
Orange, California, 92868
Nataliya Mar
- Not yet recruiting
AdventHealth Orlando
Orlando, Florida, 32804
407-303-2024
Guru Sonpavde
- Recruiting
AHN Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
412-325-5700
Shifeng Mao
- Recruiting
Providence Portland Medical Center
Portland, Oregon, 97213
Brendan Curti
- Recruiting
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Brendan Curti
- Recruiting
Kaiser Permanente Interstate Medical Office Central
Portland, Oregon, 97227
503-249-3315
Sandeep Mashru
- Not yet recruiting
Oregon Health and Science University
Portland, Oregon, 97239
Ronald Ng
- Not yet recruiting
Wilmot Cancer Institute
Rochester, New York, 14642
585-275-4823
Brendan Guercio
- Recruiting
University of California Davis (UC Davis) Comprehensive Cancer Center
Sacramento, California, 95817
916-734-3772
Mamta Parikh
- Recruiting
UCSF Medical Center at Mission Bay
San Francisco, California, 94158
773-837-0783
Vadim Koshkin
- Recruiting
Avera Cancer Institute- Research
Sioux Falls, South Dakota, 57105
Ryan Vaca
- Recruiting
Oncology Hematology Associates
Springfield, Missouri, 65807
417-882-4880
Viran Holden
- Recruiting
Washington University School of Medicine
St Louis, Missouri, 63108
Melissa Reimers
- Recruiting
US Oncology Research Network
The Woodlands, Texas, 77380
SMO Sarah Cannon Research Inst.
- Recruiting
Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer (TMPN)
Torrance, California, 90505
310-750-3300
Hugo Hool
- Recruiting
The University of Arizona Cancer Center - North Campus
Tucson, Arizona, 85719
520-626-4703
Alejandro Recio Boiles
- Recruiting
USO - Texas Oncology - Northeast Texas
Tyler, Texas, 75702
Donald Richards
- Not yet recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010
Nicholas Simon
- Not yet recruiting
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27157
980-442-6410
Earle Burgess
- Not yet recruiting
University of Massachusetts Medical School
Worcester, Massachusetts, 01655
508-856-3216
Kriti Mittal
Spain26 sites, 26 recruiting
- Not yet recruiting
Hospital Infanta Cristina
Badajoz, 06006
924218040
Marta Gonzalez Cordero
- Not yet recruiting
Institut Català d'Oncologia (ICO) - Badalona
Badalona, 08916
0034677254583
Juan Martin Liberal
- Not yet recruiting
OSI Ezkerraldea-Enkarterri-Cruces - Hospital Universitario Cruces
Barakaldo, 48903
Ricardo Fernández Rodríguez
- Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, 08035
932746000 x 4350
Rafael Morales Barrera
- Recruiting
Hospital Clínic de Barcelona
Barcelona, 08036
34 932275402
Oscar Reig Torras
- Not yet recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041
34935565638
Jose Pablo Maroto Rey
- Not yet recruiting
Hospital Universitario Reina Sofia
Córdoba, 14004
MARIA JOSE MENDEZ VIDAL
- Not yet recruiting
Hospital General Universitario de Elche
Elche, 03202
Federico Jose Vazquez Mazon
- Not yet recruiting
Institut Català d'Oncologia (ICO) - Girona
Girona, 17007
34972225834
Nuria Sala Gonzalez
- Not yet recruiting
Instituto Catalan de Oncologia - Hospital Duran i Reynals
Hospitalet, 08907
+34 932603261
Irene Ortiz Rubio
- Recruiting
Hospital Insular de Gran Canaria
Las Palmas de Gran Canaria, 35016
Alfonso Gómez de Liaño Lista
- Not yet recruiting
Hospital La Princesa
Madrid, 28006
+34915202200
Patricia Toquero Diez
- Not yet recruiting
Hospital General Universitario Gregorio Marañon
Madrid, 28009
34914265238
Jose Arranz Arija
- Not yet recruiting
MD Anderson Cancer Center
Madrid, 28033
Lucrecia Ruiz
- Recruiting
Hospital Universitario Ramón y Cajal
Madrid, 28034
(+34) 913368263
Pablo Gajate Borau
- Not yet recruiting
Hospital Clinico San Carlos
Madrid, 28040
913307545
Javier Puente Vazquez
- Recruiting
Hospital Universitario 12 de Octubre
Madrid, 28041
0034 91 390 83 39
Daniel Castellano Gauna
- Not yet recruiting
Hospital Universitario La Paz
Madrid, 28046
917277516
Alvaro Pinto Marin
- Not yet recruiting
H.R.U Málaga - Hospital General
Málaga, 29011
951308130
Alvaro Montesa Pino
- Not yet recruiting
Complejo Hospitalario de Navarra
Pamplona, 31009
8.00 - 15.00
Nuria Lainez Milagro
- Not yet recruiting
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, 28223
+34914521987
ELENA ALMAGRO CASADO
- Not yet recruiting
Hospital Universitari Sant Joan de Reus
Reus, 43204
Marc Grifoll Escoda
- Not yet recruiting
Hospital Universitario Marqués de Valdecilla
Santander, 39008
607552230
Ignacio Duran Martinez
- Not yet recruiting
CHUS - Hospital Clinico Universitario
Santiago de Compostela, 15706
34981950512
Urbano Anido Herranz
- Recruiting
Hospital Universitario Virgen Del Rocio
Seville, 41013
34955013068
Begona Perez Valderrama
- Not yet recruiting
Hospital Arnau de Vilanova
Valencia, 46015
679370073
Jose Garcia Sanchez
China25 sites, 25 recruiting
- Recruiting
Peking University First Hospital
Beijing, 100034
010-64008229
Zhisong He
- Recruiting
Peking University Third Hospital
Beijing, 100091
Shudong Zhang
- Recruiting
Beijing Cancer hospital
Beijing, 100142
Jun Guo
- Recruiting
Beijing GoBroad Hospital
Beijing, 102200
Chuanliang Cui
- Recruiting
The First Hospital of Jilin University
Changchun, 100012
Ziling Liu
- Recruiting
Xiangya Hospital Central South University
Changsha, 410008
0731-84327918
minfeng chen
- Recruiting
Hunan Cancer Hospital
Changsha, 410013
Shusuan JIANG
- Recruiting
West China Hospital, Sichuan University
Chengdu, 610066
Peng Zhang
- Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, 400016
023-89012012
Weiyang He
- Recruiting
Chongqing University Cancer Hospital
Chongqing, 400030
Fang Yuan
- Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510230
13719007083
Yongda Liu
- Recruiting
Zhujiang Hospital
Guangzhou, 510280
Manming Cao
- Recruiting
Sun Yat-Sen University Cancer Centre
Guangzhou, 511400
020-87343864
Yanxia Shi
- Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, 310014
15158885167
xiaolong Qi
- Recruiting
Sir Run Run Shaw Hospital
Hangzhou, 310016
Da Li
- Recruiting
Zhejiang Cancer Hospital
Hangzhou, 310022
Jinchao Chen
- Recruiting
Harbin Medical University Cancer Hospital
Harbin, 150081
0451-86298104
Hui Chen
- Recruiting
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, 210000
Hongqian Guo
- Recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, 530200
15877183968
Yong Tang
- Recruiting
Ningbo First Hospital
Ningbo, 315010
15958800971
Qi Ma
- Recruiting
Renji Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, 200000
862168383543
Wei Xue
- Recruiting
Huashan Hospital, Fudan University
Shanghai, 200040
Haowen Jiang
- Recruiting
Shanghai Tenth People's Hospital
Shanghai, 200072
021-66301719
Xudong Yao
- Recruiting
The Second Hospital of Tianjin Medical University
Tianjin, 300211
Hailong Hu
- Recruiting
Tongji Hospital Tongji Medical,Science & Technology
Wuhan, 430030
027-83363434
Shaogang Wang
Germany25 sites, 25 recruiting
- Not yet recruiting
Helios Klinikum Bad Saarow
Bad Saarow, 15526
0049 33631 73466
Tobias Klatte
- Not yet recruiting
Evangelisches Krankenhaus Bielefeld - Johannesstift
Bielefeld, 33611
052177275750
Florian Weissinger
- Not yet recruiting
Johanniter-Krankenhaus
Bonn, 53113
00492285432168
Carsten Ohlmann
- Not yet recruiting
Studienzentrum Bayenthal Urologische Partnerschaft Köln
Cologne, 50968
0049221362025
Jorg Klier
- Not yet recruiting
Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
Dresden, 01307
00493514584425
Severine Banek
- Not yet recruiting
Urologicum Duisburg Fachärztesozietät - Walsum
Duisburg, 47169
+49 203 5003040
Eva Hellmis
- Not yet recruiting
Universitaetsklinikum Duesseldorf
Düsseldorf, 40225
492118119353
Guenter Niegisch
- Not yet recruiting
Universitaetsklinikum Erlangen
Erlangen, 91054
+49 (0)9131 8223122
Peter Goebell
- Not yet recruiting
Universitaetsklinikum Essen
Essen, 45122
+492017232637
Viktor Gruenwald
- Not yet recruiting
Krankenhaus Nordwest GmbH
Frankfurt, 60488
496976013917
Inga Peters
- Not yet recruiting
Universitaetsklinikum Freiburg
Freiburg im Breisgau, 79106
Philippe-Fabian Pohlmann
- Not yet recruiting
Universitätsmedizin Greifswald
Greifswald, 17489
00493834865985
Cindy Roennau
- Not yet recruiting
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, 20246
040-7410-57673
Gunhild Von Amsberg
- Not yet recruiting
NCT
Heidelberg, 69120
+4962215634619
Maximilian Jenzer
- Not yet recruiting
Universitaetsklinikum des Saarlandes
Homburg, 66424
Johannes Linxweiler
- Not yet recruiting
InVO Institut für Versorgungsforschung in der Onkologie
Koblenz, 56068
+49261921569325
Christoph Lutz
- Not yet recruiting
Universitätsklinikum Schleswig-Holstein
Lübeck, 23538
045150043691
Axel Merseburger
- Not yet recruiting
Klinikum Rechts Der Isar Der Technischen Universität München
Munich, 81675
498941402522
Margitta Retz
- Not yet recruiting
Universitätsklinikum Münster - Albert Schweitzer Campus
Münster, 48149
Martin Boegemann
- Not yet recruiting
Klinikum Nürnberg Nord
Nuremberg, 90419
+ 49 911 398 3085
Marinela Augustin
- Not yet recruiting
Studienpraxis Urologie
Nürtingen, 72622
4915201622246
Tilman Todenhöfer
- Not yet recruiting
Universitätsmedizin Rostock
Rostock, 18057
+49 381 494 7801
Angelika Borkowetz
- Not yet recruiting
Universitaetsklinikum Tuebingen
Tübingen, 72076
Eva Erne
- Not yet recruiting
Universitaetsklinikum Ulm
Ulm, 89081
4973150058036
Friedemann Zengerling
- Not yet recruiting
Universitaetsklinikum Wuerzburg
Würzburg, 97080
Anna Seitz
Japan20 sites, 20 recruiting
- Recruiting
National Cancer Center Hospital
Chūōku, 104-0045
81120023812
Tatsunori Shimoi
- Recruiting
Kyushu University Hospital
Fukuoka, 812-8582
81120023812
Takashi Matsumoto
- Recruiting
Hirosaki University Hospital
Hirosaki, 036-8563
81120023812
Shingo Hatakeyama
- Recruiting
Kanazawa University Hospital
Kanazawa, 920-8641
81120023812
Hiroshi Yaegashi
- Recruiting
National Cancer Center Hospital East
Kashiwa, 277-8577
81120023812
Nobuaki Matsubara
- Recruiting
St. Marianna University Hospital
Kawasaki, 216-8511
81120023812
Eiji Kikuchi
- Recruiting
Kagawa University Hospital
Kita-ku, 761-0701
81120023812
Rikiya Taoka
- Recruiting
Kobe City Medical Center General Hospital
Kobe, 650-0047
81120023812
Toshinari Yamasaki
- Recruiting
The Cancer Institute Hospital of JFCR
Kōtoku, 135-8550
81120023812
Yuji Miura
- Recruiting
Kyoto University Hospital
Kyoto, 606-8507
81120023812
Akihiro Hamada
- Recruiting
National Hospital Organization Shikoku Cancer Center
Matsuyama, 791-0280
81120023812
Katsuyoshi Hashine
- Recruiting
Aichi Cancer Center Hospital
Nagoya, 464-8681
81120023812
Hiromichi Ebi
- Recruiting
Niigata University Medical & Dental Hospital
Niigata, 951-8520
81120023812
Tsutomu Anraku
- Recruiting
Osaka International Cancer Institute
Osaka, 541-8567
81120023812
Masashi Nakayama
- Recruiting
Gunma Prefectural Cancer Center
Otashi, 373-8550
81120023812
Masaru Hasumi
- Recruiting
Hokkaido University Hospital
Sapporo, 060-8648
81120023812
Haruka Miyata
- Recruiting
Tohoku University Hospital
Sendai, 980-8574
81120023812
Takuma Sato
- Recruiting
Iwate Medical University Hospital
Shiwa-gun Yahaba-cho, 028-3695
81120023812
Wataru Obara
- Recruiting
Tokushima University Hospital
Tokushima, 770-8503
81120023812
junya furukawa
- Recruiting
Tsukuba University Hospital
Tsukuba, 305-8576
81120023812
Yoshiyuki Nagumo
Brazil12 sites, 12 recruiting
- Not yet recruiting
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, 14784400
Rodrigo Ferreira
- Not yet recruiting
CPAM - Centro de Pesquisas da Amazônia
Belém, 66063-495
5591999809897
Bruno Fernandes
- Not yet recruiting
Hospital Tacchini
Bento Gonçalves, 95700-084
ANDRE REIRIZ
- Not yet recruiting
IOP Pesquisa
Curitiba, 82305-100
Ronald Kool
- Not yet recruiting
Hospital de Cancer de Londrina
Londrina, 86015-520
+55 43 3379-2771
Mariana Kiara
- Not yet recruiting
Liga Norte Riograndense Contra o Câncer
Natal, 59062-000
+5584991425228
Andrea Gomes
- Not yet recruiting
Hospital Nossa Senhora da Conceição
Porto Alegre, 91350-200
+55 51 35160954
Gustavo Alves
- Not yet recruiting
Instituto de Oncologia Saint Gallen
Santa Cruz do Sul, 96830-180
5551991898942
Bianca Correa Tabajara Weiss
- Not yet recruiting
Centro de Oncologia - CEON+ - Unidade São Caetano do Sul
São Caetano do Sul, 09541-270
Suelen Martins
- Not yet recruiting
Icesp - Instituto Do Câncer Do Estado de São Paulo
São Paulo, 01246-000
55 11 3893-2709
Jose Mauricio Mota
- Not yet recruiting
Hospital BP
São Paulo, 01321-001
Fabio Schutz
- Not yet recruiting
Hospital Alemao Oswaldo Cruz
São Paulo, 01327-001
1135490665
Ariel Kann
France12 sites, 12 recruiting
- Not yet recruiting
Institut de Cancérologie de l'Ouest
Angers, 49055
33241352700
Sophie Abadie-Lacourtoisie
- Recruiting
CHU de Bordeaux Hop St ANDRE
Bordeaux, 33075
+33556794708
Marine Gross-Goupil
- Not yet recruiting
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, 33076
Diego Teyssonneau
- Not yet recruiting
CHRU de Brest
Brest, 29609
Benjamin Auberger
- Not yet recruiting
Centre François Baclesse
Caen, 14076
Florence Joly-Lobbedez
- Not yet recruiting
Centre Oscar Lambret
Lille, 59020
0033 (0)320009757
Yaovi AMELA
- Recruiting
Centre Leon Berard
Lyon Cedex08, 69373
33478782643
Aude Flechon
- Not yet recruiting
Institut Paoli-Calmettes
Marseille, 13273
Gwenaelle Gravis
- Not yet recruiting
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire Carém -T
Nîmes, 30029
Leticia Aptecar
- Not yet recruiting
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310
33478864324
Denis Maillet
- Not yet recruiting
Oncopole Claudius Regaud
Toulouse, 31059
Damien POUESSEL
- Recruiting
Gustave Roussy
Villejuif, 94800
33142115276
Yohann Loriot
Poland12 sites, 12 recruiting
- Not yet recruiting
IN VIVO
Bydgoszcz, 85-048
48888455614
Anna Krause
- Not yet recruiting
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie
Koszalin, 75-581
48502204953
Mariusz Kwiatkowski
- Not yet recruiting
Pratia MCM Krakow
Krakow, 30-727
48 505 169 040
Anna Drosik Kwasniewska
- Not yet recruiting
AIDPORT Sp. z o.o.
Skórzewo, 60-185
Piotr Tomczak
- Not yet recruiting
GYNCENTRUM Szpital
Sosnowiec, 41-208
Sylwia Szablowska-Siwik
- Not yet recruiting
Luxmed Onkologia sp. z o. o.
Warsaw, 01-748
Pawel Morawski
- Not yet recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warsaw, 02-781
48225462433
Pawel Wiechno
- Not yet recruiting
WSD MEDI
Warsaw, 02-786
Anna Wasko Grabowska
- Not yet recruiting
Medical Concierge Centrum Medyczne
Warsaw, 02-798
602300992
Piotr Radziszewski
- Not yet recruiting
Szpital Grochowski im. dr med. Rafała Masztaka SPZOZ
Warsaw, 04-073
48 22 5152 591
Iwona Skoneczna
- Not yet recruiting
Wojskowy Instytut Medyczny Państwowy Instytut Badawczy
Warsaw, 04-141
Szymon Borowiec
- Not yet recruiting
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
Wrocaw, 50-556
Anna Kolodziej
Taiwan11 sites, 11 recruiting
- Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
Wen-Jeng Wu
- Recruiting
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung Niao Sung Dist, 83301
886-972919696
Yu-Li Su
- Recruiting
China Medical University Hospital
Taichung, 404332
Chao-Hsiang Chang
- Recruiting
Taichung Veterans General Hospital
Taichung, 407
Jian-Ri Li
- Not yet recruiting
National Cheng Kung University Hospital
Tainan, 704
0980971870
Wen-Pin Su
- Recruiting
Chi Mei Medical Center
Tainan, 71004
Nai-Wen Kang
- Recruiting
Chi Mei Hospital - Liouying Branch
Tainan, 73657
Yen-Hsun Chen
- Recruiting
National Taiwan University Hospital
Taipei, 10002
Yu-Chieh Tsai
- Recruiting
National Taiwan University Cancer Center (NTUCC)
Taipei, 106
Ying-Chun Shen
- Recruiting
Taipei Veterans General Hospital
Taipei, 11217
886228757519-323
Yi-Hsiu Huang
- Recruiting
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, 333
886-3-3281200
See-Tong Pang
Turkey (Türkiye)11 sites, 11 recruiting
- Not yet recruiting
Adana Medical Park Seyhan Hastanesi
Adana, 01140
905325005269
Ali Besen
- Not yet recruiting
Sakarya University School of Medicine
Adapazarı, 54100
+90 5054785576
Ilhan Hacibekiroglu
- Not yet recruiting
Ankara University Health Practice and Research Hospitals
Ankara, 06100
00903125957321
Yuksel Urun
- Not yet recruiting
Ankara Bilkent Şehir Hastanesi
Ankara, 06800
905555306271
Mehmet Ali Nahit Sendur
- Not yet recruiting
Antalya Egitim ve Arastırma Hastanesi
Antalya, 07100
905336488217
Derya KIVRAK SALIM
- Not yet recruiting
Dicle Üniversitesi
Diyarbakır, 21200
90 5337677131
Muhammet kaplan
- Not yet recruiting
Trakya University
Edirne, 22030
90 5334364678
Muhammet Hacioglu
- Not yet recruiting
Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
Gaziantep, 27310
05065118207
tulay kus
- Not yet recruiting
Marmara Universitesi Pendik Egitim Arastirma Hastanesi
Istanbul, 34899
905433389339
Murat Sari
- Not yet recruiting
zmir Katip Çelebi Üniversitesi Atatürk Eitim Ve Aratrma Hastanesi
Izmir, 35360
905324078648
Ahmet Alacacioglu
- Not yet recruiting
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Kadıköy, 34722
Mahmut Gumus
South Korea10 sites, 10 recruiting
- Recruiting
National Cancer Center
Goyang-si, 10408
Ho Kyung Seo
- Recruiting
Chungnam national university hospital
Junggu, 35015
Hyo Jin Lee
- Recruiting
Gachon University Gil Medical Center
Namdong-gu, 21565
Joo-Hwan Park
- Recruiting
Seoul National University Bundang Hospital
Seongnam, 13620
820317877842
Eun Hee Jung
- Recruiting
Seoul National University Hospital
Seoul, 03080
82-2-2072-4035
Miso Kim
- Recruiting
Severance Hospital, Yonsei University Health System
Seoul, 03722
82222288138
Sang Joon Shin
- Recruiting
Asan Medical Center
Seoul, 05505
82-2-3010-3266
Inkeun Park
- Recruiting
Samsung Medical Center
Seoul, 06351
82-2-3410-3459
Se Hoon Park
- Recruiting
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, 06591
82-10-9056-6116
In-Ho Kim
- Recruiting
Ewha Womans University Mokdong Hospital
Seoul, 07985
Jungmin Jo
Australia9 sites, 9 recruiting
- Recruiting
Box Hill Hospital
Box Hill, 3128
Iris Tung
- Recruiting
Mater Misericordiae Limited
Brisbane, 4101
Niara Oliveira
- Recruiting
GenesisCare - Campbelltown
Campbelltown, 2560
Felicia Roncolato
- Recruiting
Austin Health
Heidelberg, 3084
+61420381848
Andrew Weickhardt
- Recruiting
Macquarie University
Macquarie University, 2109
0402856430
Alison Zhang
- Recruiting
Sir Charles Gairdner Hospital
Perth, 6009
Rajiv Shinde
- Recruiting
Prince of Wales Hospital
Randwick, 2031
Elizabeth Hovey
- Recruiting
Western Health-Sunshine & Footscray Hospitals
St Albans, 3021
412139261
Shirley Wong
- Recruiting
Calvary Mater Newcastle
Waratah, 2298
Lucy Corke
Italy8 sites, 8 recruiting
- Not yet recruiting
Instituto Tumori Giovanni Paolo II
Bari, 70124
+39 0805555391
Marica Gentile
- Not yet recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133
0390223903028
Giuseppe Procopio
- Not yet recruiting
Ospedale San Raffaele
Milan, 20132
+390226435789
Andrea Necchi
- Not yet recruiting
Azienda Ospedaliera Universitaria Federico II
Naples, 80131
+393404166268
Luigi Formisano
- Not yet recruiting
Istituto Oncologico Veneto IRCCS
Padova, 35128
+390423732137
Marco Maruzzo
- Not yet recruiting
Azienda Ospedaliera Universitaria Pisana
Pisa, 56126
Luca Galli
- Not yet recruiting
Fondazione Policlinico Universitario Agostino Gemelli
Roma, 00168
390630154838
Roberto Iacovelli
- Not yet recruiting
Istituto Nazionale Tumori Regina Elena
Rome, 00144
Fabio Calabro
United Kingdom7 sites, 7 recruiting
- Recruiting
Huddersfield Royal Infirmary
Huddersfield, HD3 3EA
Ursula Hofmann
- Recruiting
St Bartholomew's Hospital
London, EC1A 7BE
02078828494
Thomas Powles
- Recruiting
University College London Hospital
London, NW1 2PG
Ursula McGovern
- Recruiting
Royal Marsden Hospital (Sutton)
London, SM2 5PT
+44 (0) 2086613529
Robert Huddart
- Recruiting
Royal Marsden Hospital (Chelsea)
London, SW3 6JJ
+44 (0) 2086613529
Robert Huddart
- Recruiting
The Christie NHS Foundation Trust
Manchester, M20 4BX
01614468409
Yee Pei Song
- Not yet recruiting
Weston Park Hospital
Sheffield, S10 2SJ
Syed Hussain
Czechia6 sites, 6 recruiting
- Not yet recruiting
Masarykuv onkologicky ustav
Brno, 656 53
420 543 132 216
Alexandr Poprach
- Not yet recruiting
Fakultni nemocnice Hradec Kralove
Hradec Králové, 500 05
420495832176
Jindrich Kopecky
- Not yet recruiting
Fakultni nemocnice Olomouc
Olomouc, 779 00
+420 588 444 717
Hana Studentova
- Not yet recruiting
Fakultni nemocnice Kralovske Vinohrady
Prague, 10034
420267162837
Jan Dvorak
- Not yet recruiting
Fakultni Thomayerova nemocnice
Prague, 14059
420 728177828
Michaela Matouskova
- Not yet recruiting
Fakultni nemocnice Motol
Prague, 150 06
420734236410
Tomas Buchler
Denmark5 sites, 5 recruiting
- Not yet recruiting
Aalborg Universitetshospital, Syd
Aalborg, 9000
004597661410
Andreas Carus
- Not yet recruiting
Aarhus Universitetshospital, Skejby
Aarhus, 8200
Mads Agerbaek
- Not yet recruiting
Rigshospitalet
Copenhagen, 2100
4535458403
Helle Pappot
- Not yet recruiting
Herlev and Gentofte Hospital
Copenhagen, 2730
4538681079
Line Dohn
- Not yet recruiting
Næstved Sygehus
Næstved, 4700
Anne Sørensen
Hungary5 sites, 5 recruiting
- Not yet recruiting
Semmelweis Egyetem
Budapest, 1082
Peter Nyirady
- Not yet recruiting
Országos Onkológiai Intézet
Budapest, 1122
3612248600
Lajos Geczi
- Not yet recruiting
Debreceni Egyetem Klinikai Kozpont
Debrecen, 4032
3652255840
Peter Arkosy
- Not yet recruiting
Szabolcs Szatmár Bereg Vármegyei Oktatókórház
Nyíregyháza, 4400
003642599700 EXT 2334
Ágnes Wéber
- Not yet recruiting
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, 6725
Aniko Maraz
Canada4 sites, 4 recruiting
- Not yet recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, T2N 5G2
Nimira Alimohamed
- Not yet recruiting
Hamilton Health Sciences-Juravinski Cancer Centre
Hamilton, L8V5C2
Arani Sathiyapalan
- Not yet recruiting
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus
Québec, G1J 1Z4
Antoine Morin Coulombe
- Not yet recruiting
BC Cancer Vancouver
Vancouver, V5Z 4E6
Bernhard Eigl
Netherlands4 sites, 4 recruiting
- Not yet recruiting
Amsterdam UMC, locatie VUmc
Amsterdam, 1081 HV
+31(0)20-4444321
Jens Voortman
- Not yet recruiting
Amphia Ziekenhuis, locatie Breda Molengracht
Breda, 4818 CK
+31 76 595 5146
Hans Westgeest
- Not yet recruiting
Radboudumc
Nijmegen, 6525 GA
+31 (0)24 3610353
Mira Franken
- Not yet recruiting
Erasmus Medisch Centrum
Rotterdam, 3015 GD
+31618842777
Debbie Robbrecht
About this study
Official title: FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab.
Study participation could last up to approximately 6 years.
- Being tested
- Vepugratinib, Placebo, EV, Pembrolizumab
- Keywords
- FGFR3, Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
- Medical subject headings
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VepugratinibDrug
Administered orally
PlaceboOther
Administered orally
EVDrug
Administered by IV infusion
PembrolizumabDrug
Administered by IV infusion
| Study group | Role | What they receive |
|---|---|---|
| Vepugratinib + EV + Pembrolizumab (Safety Lead In) | Experimental | Vepugratinib administered orally with EV + pembrolizumab administered IV Receives: Drug: Vepugratinib; Drug: EV; Drug: Pembrolizumab |
| Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab | Experimental | Vepugratinib administered orally, and EV + pembrolizumab administered by intravenous (IV) infusion. Receives: Drug: Vepugratinib; Drug: EV; Drug: Pembrolizumab |
| Placebo + EV + Pembrolizumab | Placebo comparator | Placebo administered orally, and EV + pembrolizumab administered by IV infusion. Receives: Other: Placebo; Drug: EV; Drug: Pembrolizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab
Measured: From baseline up to 90 months
Safety Lead-in: Overall Response Rate (ORR)
ORR by Investigator Assessment.
Measured: From baseline up to 90 months
Progression-free Survival (PFS)
PFS by blinded independent committee review (BICR).
Measured: Baseline to Study Completion (estimated as 6 years)
Secondary outcomes (11)
Safety Lead-in: Disease Control Rate (DCR)
DCR by investigator assessment.
Measured: From baseline up to the end of Cycle 2 (each Cycle is 21 days)
Safety Lead-in: Time to Response (TTR)
TTR by investigator assessment.
Measured: From baseline up to 90 months
Overall Survival (OS)
Measured: Baseline to Study Completion (estimated as 6 years)
Objective Response Rate (ORR) by BICR
Measured: Baseline to Study Completion (estimated as 6 years)
Duration of Response (DoR)
DOR by BICR.
Measured: Baseline to Study Completion (estimated as 6 years)
Progression-free Survival (PFS)
PFS by investigator assessment.
Measured: Baseline to Study Completion (estimated as 6 years)
Objective Response Rate (ORR)
Percentage of Participants who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)ORR by investigator assessment
Measured: Baseline to Study Completion (estimated as 6 years)
Duration of Response (DOR)
DOR by investigator assessment.
Measured: Baseline to Study Completion (estimated as 6 years)
Progression-free Survival 2 (PFS2)
PFS2 by investigator assessment.
Measured: Baseline to Study Completion (estimated as 6 years)
Plasma Concentrations of Vepugratinib
PK samples are to be drawn every odd cycle while participant on study.
Measured: Cycle 1 Day 1 to Study completion (estimated as 90 months)
Change from Baseline in Global Health Status/Quality of Life (QOL) and Physical Function Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 is a validated self-reported general cancer questionnaire consisting of 30 items with a recall of the past 7 days. Response options range from 1) "very poor" to 7) "excellent." Higher scores represent better overall HRQoL.
Measured: Baseline to Study Completion (estimated as 6 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2025
- Study start12 Dec 2025
- Primary completionOct 2029 (estimated)
- Study completionMay 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carcinoma, Transitional CellStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07218380
- Sponsor's protocol ID
- 27333
- Other IDs
- J4G-MC-JZVD, 2025-522855-25-00, 2025
- Acronym
- FORAGER-2
- Status last verified
- Oct 2026
- First submitted
- 9 Oct 2025
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
- ClinicalTrials.gov ID
- NCT07218380
- Acronym / sponsor ID
- FORAGER-2 / 27333
- Keywords
- FGFR3, Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 12 Dec 2025 (actual)
- Primary completion
- Oct 2029 (estimated)
- Study completion
- May 2033 (estimated)
- First posted
- 20 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab.
Study participation could last up to approximately 6 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Vepugratinib + EV + Pembrolizumab (Safety Lead In) | Experimental | Drug: Vepugratinib, Drug: EV, Drug: PembrolizumabVepugratinib administered orally with EV + pembrolizumab administered IV |
| Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab | Experimental | Drug: Vepugratinib, Drug: EV, Drug: PembrolizumabVepugratinib administered orally, and EV + pembrolizumab administered by intravenous (IV) infusion. |
| Placebo + EV + Pembrolizumab | Placebo comparator | Other: Placebo, Drug: EV, Drug: PembrolizumabPlacebo administered orally, and EV + pembrolizumab administered by IV infusion. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present.
- Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer.
- Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Have adequate laboratory parameters
Key exclusion criteria (5 listed)
- Have received prior systemic therapy for locally advanced or metastatic urothelial cancer (mUC).
- Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria for Adverse Events ([CTCAE] version 5.0) from prior neoadjuvant or adjuvant systemic therapy.
- Have ongoing sensory or motor neuropathy of Grade 2 or higher
- Have untreated or uncontrolled central nervous system (CNS) involvement or any history of leptomeningeal disease.
- Current evidence corneal keratopathy or retinal disorder confirmed by ocular examination at screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VepugratinibAdministered orally | Drug | Vepugratinib + EV + Pembrolizumab (Safety Lead In), Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab |
| PlaceboAdministered orally | Other | Placebo + EV + Pembrolizumab |
| EVAdministered by IV infusion | Drug | Placebo + EV + Pembrolizumab, Vepugratinib + EV + Pembrolizumab (Safety Lead In), Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab |
| PembrolizumabAdministered by IV infusion | Drug | Placebo + EV + Pembrolizumab, Vepugratinib + EV + Pembrolizumab (Safety Lead In), Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab |
Primary outcome
Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab
Time frame: From baseline up to 90 months
Safety Lead-in: Overall Response Rate (ORR)
Time frame: From baseline up to 90 months
ORR by Investigator Assessment.
Progression-free Survival (PFS)
Time frame: Baseline to Study Completion (estimated as 6 years)
PFS by blinded independent committee review (BICR).
11 secondary outcomes
Safety Lead-in: Disease Control Rate (DCR)
Time frame: From baseline up to the end of Cycle 2 (each Cycle is 21 days)
Safety Lead-in: Time to Response (TTR)
Time frame: From baseline up to 90 months
Overall Survival (OS)
Time frame: Baseline to Study Completion (estimated as 6 years)
Objective Response Rate (ORR) by BICR
Time frame: Baseline to Study Completion (estimated as 6 years)
Duration of Response (DoR)
Time frame: Baseline to Study Completion (estimated as 6 years)
Progression-free Survival (PFS)
Time frame: Baseline to Study Completion (estimated as 6 years)
Objective Response Rate (ORR)
Time frame: Baseline to Study Completion (estimated as 6 years)
Duration of Response (DOR)
Time frame: Baseline to Study Completion (estimated as 6 years)
Progression-free Survival 2 (PFS2)
Time frame: Baseline to Study Completion (estimated as 6 years)
Plasma Concentrations of Vepugratinib
Time frame: Cycle 1 Day 1 to Study completion (estimated as 90 months)
Change from Baseline in Global Health Status/Quality of Life (QOL) and Physical Function Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Time frame: Baseline to Study Completion (estimated as 6 years)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Lilly Trials siteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Carcinoma, Transitional Cell
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
Registry Platform Urologic Cancer
Renal Cell Carcinoma, Urothelial Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
276 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Vepugratinib, EV and Pembrolizumab in people with Carcinoma, Transitional Cell and Urinary Bladder Neoplasms, run by Eli Lilly and Company at 276 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 276 sites in United States, Spain, China, Germany, Japan and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (1-317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab (time frame: From baseline up to 90 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.